数据显示，诺安基金旗下1只基金位居五洲医疗十大流通股东。诺安多策略混合A（320016）二季度增 持18.16万股，持有股数32.79万股，占流通股的比例为1.78%。根据测算，今日浮盈赚取约79.35万元。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模13.99亿。今年以来收益61.81%，同类 排名429/8174；近一年收益121.96%，同类排名230/7981；成立以来收益212.3%。 诺安多策略混合A（320016）基金经理为孔宪政、王海畅。 截至发稿，孔宪政累计任职时间4年291天，现任基金资产总规模46.07亿元，任职期间最佳基金回报 75.42%， 任职期间最差基金回报-16.74%。 9月12日，五洲医疗涨5.24%，截至发稿，报48.64元/股，成交5668.95万元，换手率1.76%，总市值33.08 亿元。 资料显示，安徽宏宇五洲医疗器械股份有限公司位于安徽省安庆市太湖县经济开发区观音路2号，成立 日期2011年4月15日，上市日期2022年7月5日，公司主营业务涉及一次性使用无菌输注类医疗器械的研 发、生产、销售以及其他诊断、护理等相关医疗用品的集成供应, ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司本次活动采用网络远程的方式举行，投资者可登录"全景路演"网站（https://rs.p5w.net），或关注微 信公众号：全景财经，或下载全景路演APP参与本次互动交流，活动时间为2025年9月15日（星期一） 15:00-17:00。届时公司将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可 持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告。 安徽宏宇五洲医疗器械股份有限公司 证券代码：301234 证券简称：五洲医疗 公告编号：2025-028 关于参加2025年安徽辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或者重大 遗漏。 为进一步加强与投资者的互动交流，安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）将参加由 安徽证监局指导，安徽上市公司协会与深圳市全景网络有限公司联合举办的"2025年安徽上市公司投资 者网上集体接待日"活动，现将相关事项公告如下： 安徽宏宇五洲医疗器械股份有限公司 二〇二五年九月九日 ...

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有限公司 2025年半年度持续督导跟踪报告 | 保荐机构名称：光大证券股份有限公司 | 被保荐公司简称：五洲医疗 | | --- | --- | | 保荐代表人姓名：黄腾飞 | 联系电话：021-22169999 | | 保荐代表人姓名：林剑云 | 联系电话：021-22169999 | 一、保荐工作概述 1 | （1）发表专项意见次数 | 次 2 | | --- | --- | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 次 0 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8．关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 无 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 次 0 | | （2）培训日期 | 不适 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-028 公司本次活动采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP 参与本次互动交流，活动时间为 2025 年 9 月 15 日（星期一）15:00-17:00。届 时公司将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权激 励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与。 特此公告。 安徽宏宇五洲医疗器械股份有限公司 二〇二五年九月九日 安徽宏宇五洲医疗器械股份有限公司 关于参加 2025 年安徽辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，安徽宏宇五洲医疗器械股份有限公司 （以下简称"公司"）将参加由安徽证监局指导，安徽上市公司协会与深圳市全 景网络有限公司联合举办的"2025 年安徽上市公司投资者网上集体接待日"活 动，现将相关事项公告如下： ...

Group 1 - The company Wuzhou Medical (301234) responded to investor inquiries on August 26, indicating that as of August 20, 2025, the total number of shareholders is 6,048 [1]

Core Viewpoint - The company, Wuzhou Medical, has seen a significant increase in stock price and trading volume, benefiting from the depreciation of the RMB and its classification as a "specialized and innovative" enterprise [1][2][3]. Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, and other medical supplies [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022. Its main revenue sources include syringes (41.29%), medical puncture needles (25.51%), and infusion/blood transfusion devices (20.92%) [7]. Financial Performance - For the first half of 2025, Wuzhou Medical reported a revenue of 217 million yuan, representing a year-on-year growth of 2.26%. However, the net profit attributable to shareholders decreased by 51.69% to 10.51 million yuan [7]. - As of July 31, the company had a total market capitalization of 3.17 billion yuan [1]. Market Position and Recognition - Wuzhou Medical's overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company has been recognized as a "specialized and innovative" small giant enterprise, which is a prestigious title in China, indicating its strong market position and innovation capabilities [3]. Stock Market Activity - On August 26, the stock price of Wuzhou Medical increased by 7.42%, with a trading volume of 239 million yuan and a turnover rate of 7.56% [1]. - The average trading cost of the stock is 40.50 yuan, and it is currently near a resistance level of 47.98 yuan, indicating potential for upward movement if this level is surpassed [6]. Shareholder Information - As of June 30, 2025, the top ten circulating shareholders include notable funds, with one fund increasing its holdings by 18.16 million shares [9]. - The number of shareholders has increased by 13.24% to 7,255 [7]. Dividend Information - Since its A-share listing, Wuzhou Medical has distributed a total of 81.6 million yuan in dividends [8].

Core Insights - The number of shareholders in Wuzhou Medical decreased to 6,048 as of August 20, 2025, representing a decline of 1,207 shareholders or 16.64% compared to the previous period [1] - The average shareholding per shareholder increased from 9,400 shares to 11,200 shares, while the average market value of shares held rose from 377,000 yuan to 458,200 yuan [1] - During the same period, Wuzhou Medical's stock price increased by 11.78% [1] Shareholder Statistics - As of August 20, 2025, the number of shareholders was 6,048, with an average shareholding of 11,200 shares and an average market value of 458,200 yuan [1] - On July 31, 2025, the number of shareholders was 7,255, with an average shareholding of 9,400 shares and an average market value of 377,000 yuan [1] - Historical data shows fluctuations in shareholder numbers and average holdings from March to August 2025, indicating a trend towards increased concentration of shareholding [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Wuzhou Medical, which has a high PE ratio compared to its industry peers [1][2] - Wuzhou Medical's closing price on August 25 was 43.4 yuan, with a PE ratio of 102.77 and a total market capitalization of 2.951 billion yuan [1] - The company operates in the medical device sector, focusing on the research, manufacturing, and sales of disposable sterile infusion medical devices, with a product portfolio that includes syringes and infusion devices [1] Group 2 - As of the 2025 semi-annual report, Wuzhou Medical reported revenue of 217 million yuan, a slight decrease of 2.26% year-on-year, and a net profit of 10.5151 million yuan, reflecting a significant decline of 51.69% year-on-year [1] - The company's gross profit margin stands at 14.33%, indicating challenges in maintaining profitability [1] - In terms of institutional holdings, only two institutions hold shares in Wuzhou Medical, with a total of 478,600 shares valued at 1.4 million yuan [1]

Group 1 - The stock price of Wuzhou Medical reached 42.22 yuan as of August 22, 2025, with an increase of 1.96% compared to the previous trading day [1] - During the trading session, the stock experienced a rapid rebound, with a rise of over 2% within 5 minutes, peaking at 43.34 yuan and achieving a trading volume of 1.55 billion yuan [1] - On August 22, the net inflow of main funds into Wuzhou Medical was 7.49 million yuan, with a cumulative net inflow of 23.23 million yuan over the past five days [1] Group 2 - Wuzhou Medical operates in the medical device sector, focusing on the research, production, and sales of medical consumables, including syringes and infusion devices [1]

Company Overview - Wuzhou Medical closed at 42.22 yuan, up 1.96%, with a rolling PE ratio of 99.97 times and a total market value of 2.871 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 56.95 times and a median of 40.49 times [1] Shareholder Information - As of July 31, 2025, Wuzhou Medical had 7,255 shareholders, an increase of 848 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Anhui Hongyu Wuzhou Medical Device Co., Ltd. specializes in the R&D, manufacturing, and sales of disposable sterile infusion medical devices, along with other diagnostic and nursing supplies [1] - The main products include syringes, infusion and blood transfusion devices, medical puncture needles, and other diagnostic and clinical care products [1] - The company holds 46 medical device product registration and filing certificates as of the reporting period [1] Financial Performance - In the latest semi-annual report for 2025, the company achieved operating revenue of 217 million yuan, a decrease of 2.26% year-on-year, and a net profit of 10.5151 million yuan, down 51.69% year-on-year, with a gross sales margin of 14.33% [1]